Mortality Related to Chronic Obstructive Pulmonary Disease During the COVID-19 Pandemic: An Analysis of Multiple Causes of Death Through Different Epidemic Waves in Veneto, Italy
Overview
Public Health
Authors
Affiliations
Mortality related to chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic is possibly underestimated by sparse available data. The study aimed to assess the impact of the pandemic on COPD-related mortality by means of time series analyses of causes of death data. We analyzed the death certificates of residents in Veneto (Italy) aged ≥40 years from 2008 to 2020. The age-standardized rates were computed for COPD as the underlying cause of death (UCOD) and as any mention in death certificates (multiple cause of death-MCOD). The annual percent change (APC) in the rates was estimated for the pre-pandemic period. Excess COPD-related mortality in 2020 was estimated by means of Seasonal Autoregressive Integrated Moving Average models. Overall, COPD was mentioned in 7.2% (43,780) of all deaths. From 2008 to 2019, the APC for COPD-related mortality was -4.9% (95% CI -5.5%, -4.2%) in men and -3.1% in women (95% CI -3.8%, -2.5%). In 2020 compared to the 2018-2019 average, the number of deaths from COPD (UCOD) declined by 8%, while COPD-related deaths (MCOD) increased by 14% (95% CI 10-18%), with peaks corresponding to the COVID-19 epidemic waves. Time series analyses confirmed that in 2020, COPD-related mortality increased by 16%. Patients with COPD experienced significant excess mortality during the first year of the pandemic. The decline in COPD mortality as the UCOD is explained by COVID-19 acting as a competing cause, highlighting how an MCOD approach is needed.
Qamar A, Hui L Medicine (Baltimore). 2024; 103(48):e40730.
PMID: 39612440 PMC: 11608673. DOI: 10.1097/MD.0000000000040730.
Fihel A, Janicka A, Buschner A, Ustinaviciene R, Trakiene A PLoS One. 2024; 19(7):e0307194.
PMID: 39012883 PMC: 11251637. DOI: 10.1371/journal.pone.0307194.
Lam G, Wen C, Ronksley P, Bakal J, Bhutani M, Soril L Ann Am Thorac Soc. 2024; 21(9):1281-1288.
PMID: 38820253 PMC: 11376357. DOI: 10.1513/AnnalsATS.202312-1078OC.
Baumert J, Scheidt-Nave C, Steppuhn H, Tetzlaff F, Kraywinkel K, An der Heiden M Dtsch Arztebl Int. 2024; 121(4):135-136.
PMID: 38518297 PMC: 11019757. DOI: 10.3238/arztebl.m2023.0262.
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu C, Cui W, Lei Y, Tang Y, Zhang Y, Su Q Infect Drug Resist. 2023; 16:7797-7808.
PMID: 38148771 PMC: 10750493. DOI: 10.2147/IDR.S433186.